Veerendra Munugalavadla has not added Biography.
If you are Veerendra Munugalavadla and would like to personalize this page please email our Author Liaison for assistance.
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer discovery 03, 2020 | Pubmed ID: 31915195
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet (London, England) 04, 2020 | Pubmed ID: 32305093
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer Oct, 2020 | Pubmed ID: 32757302
Acerta Pharma, AstraZeneca Group
Paola Marco-Casanova1,
Natalia Lukashchuk1,
Benedetta Lombardi1,
Veerendra Munugalavadla2,
Melanie M. Frigault3,
Elizabeth A. Harrington1,
J. Carl Barrett3,
Andrew J. Pierce1
1Translational Medicine, R&D Oncology, AstraZeneca,
2, Acerta Pharma, AstraZeneca Group,
3Translational Medicine, R&D Oncology, AstraZeneca
Конфиденциальность
Условия эксплуатации
Политика
СВЯЖИТЕСЬ С НАМИ
РЕКОМЕНДОВАТЬ БИБЛИОТЕКЕ
НОВОСТИ JoVE
Исследования
JoVE Journal
Подборки методов
JoVE Encyclopedia of Experiments
Архив
Образование
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Business
JoVE Quiz
JoVE Playlist
АВТОРЫ
Библиотекарь
Доступ
О JoVE
JoVE Sitemap
Авторские права © 2025 MyJoVE Corporation. Все права защищены